U.S. FDA extends review of Humacyte blood vessel implant
Humacyte U.S. health regulator said it has expanded the company’s authority to test an implant that can replace a damaged or injured blood vessel, causing its shares to fall more than 15% after the close of trading.
POPULAR POSTS
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVE STREAM